熱門資訊> 正文
CASI Pharmaceuticals宣布1500万美元私募融资
2024-06-27 04:15
- 英創遠達製藥(CASI) 0
- Healthcare Capital Corp Class A(HCCC) 0
- Healthcare Capital Corp Warrants 2020- on Healthcare Capital(HCCCW) 0
- CASI Pharmaceuticals (NASDAQ:CASI) on Wednesday said it has entered into securities purchase agreements with certain investors for a private investment in public equity financing that is expected to result in aggregate gross proceeds of about $15 million.
- The PIPE transaction is being led by Venrock Healthcare Capital Partners and Foresite Capital, with participation by Panacea Venture and Dr. Wei-Wu He, the Chairman of the board of directors and CEO of the company and his family trust.
- In the PIPE transaction, CASI is selling an aggregate of 1.02M ordinary shares of the company, at a price of $5.00 per ordinary share, and in the case of two investors, pre-funded warrants to purchase up to an aggregate of 1.98M ordinary shares at a per-share pre-funded exercise price of $4.9999.
- Each pre-funded warrant will have an exercise price of $0.0001 per share.
- The PIPE transaction is expected to close in mid-July 2024.
- Source: Press Release
More on CASI Pharmaceuticals
- Casi Pharma spikes as FDA clears clinical trial for blood disorder therapy
- Seeking Alpha’s Quant Rating on CASI Pharmaceuticals
- Historical earnings data for CASI Pharmaceuticals
- Financial information for CASI Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
